SinoMab BioScience Limited (3681.HK)

HKD 1.24

(5.98%)

Total Liabilities Summary of SinoMab BioScience Limited

  • SinoMab BioScience Limited's latest annual total liabilities in 2023 was 552.2 Million CNY , up 10.71% from previous year.
  • SinoMab BioScience Limited's latest quarterly total liabilities in 2024 Q2 was 564.87 Million CNY , down 0.0% from previous quarter.
  • SinoMab BioScience Limited reported annual total liabilities of 498.77 Million CNY in 2022, up 38.0% from previous year.
  • SinoMab BioScience Limited reported annual total liabilities of 361.42 Million CNY in 2021, up 153.61% from previous year.
  • SinoMab BioScience Limited reported quarterly total liabilities of 552.2 Million CNY for 2023 FY, up 10.71% from previous quarter.
  • SinoMab BioScience Limited reported quarterly total liabilities of 552.2 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of SinoMab BioScience Limited (2023 - 2017)

Historical Annual Total Liabilities of SinoMab BioScience Limited (2023 - 2017)

Year Total Liabilities Total Liabilities Growth
2023 552.2 Million CNY 10.71%
2022 498.77 Million CNY 38.0%
2021 361.42 Million CNY 153.61%
2020 142.51 Million CNY -6.4%
2019 152.24 Million CNY 147.91%
2018 61.41 Million CNY -71.11%
2017 212.58 Million CNY 0.0%

Peer Total Liabilities Comparison of SinoMab BioScience Limited

Name Total Liabilities Total Liabilities Difference
Uni-Bio Science Group Limited 152.81 Million HKD -261.347%
CK Life Sciences Int'l., (Holdings) Inc. 7.05 Billion HKD 92.176%